The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 11, 2005, Pages 6290-6295

  Bhayana, Shelly ^a,e   Booth, Gillian L ^b   Asa, Sylvia L ^c,d   Kovacs, Kalman ^b,d   Ezzat, Shereen ^a,e,f  

^a Pediatric Oral and Maxillofacial Surgery   (Canada)

^b ST MICHAEL'S HOSPITAL   (United Kingdom)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Department of Laboratory Medicine and Pathobiology ^*  (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HORMONE BLOOD LEVEL; HUMAN; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; AGED; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCTREOTIDE; PHENOTYPE; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 27544470454     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0998     Document Type: Article

References (27)

1. American Association of Clinical Endocrinologists Acromegaly Guidelines Task Force 2004 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10:213-225
2. Fazio S, Cittadini A, Merola CB, Sabatini D, Colao A, Biondi B, Lombardi G, Sacca L 1994 Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 79:441-446
3. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F 2001 Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 4:259-262
4. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni Jr JF 2002 Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395-400
5. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
6. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G 2000 Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
7. Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scarpa R, Smaltino F, Lombardi G 1999 Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 51:611-618
8. Grunstein RR, Ho KK, Sullivan CE 1994 Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121:478-483
9. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB 1998 Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418
10. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
11. Melmed S 1998 Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab 83:3409-3410
12. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407-413
13. Lamberts SW, Del Pozo E 1988 Somatostatin analog treatment of acromegaly: new aspects. Horm Res 29:115-117
14. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
15. Bevan JS 2005 Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
16. Ezzat S, Horvath E, Harris AG, Kovacs K 1994 Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79:113-118
17. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Samo A, Longobardi S, Merola B, Salvatore M, Lombardi G 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362
18. Asa SL 1998 Tumors of the pituitary gland. Atlas of tumor pathology, 3rd Series, Fascicle 22. Washington DC: Armed Forces Institute of Pathology
19. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K 1995 In vivo responsiveness of morphological variants of growth hormoneproducing pituitary adenomas to octreotide. Eur J Endocrinol 133:686-690
20. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 Tumours of endocrine organs. World Health Organization Classification of Tumours. Lyons: IARC
21. Hardy J 1968 Transphenoidal microsurgery of the normal and pathological pituitary. In: Clinical neurosurgery. Proceedings of the Congress of Neurological Surgeons. Baltimore: Williams & Wilkins; 185-217
22. s and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566-568
23. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L 1989 GTPase inhibiting mutations activate the α-chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 340:692-696
24. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G 1990 Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421-1426
25. Asa SL, Ezzat S 2002 The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836-849
26. Kreutzer J, Vance ML, Lopes MB, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077
27. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73:233-240